Loading...

Stock Performance

Data Provided by Refinitiv. Minimum 15 minutes delayed.


小麦加速器免费永久加速-快连加速器app

July 31, 2024 - Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results July 7, 2024 - Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA) July 2, 2024 - Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

小麦加速器免费永久加速-快连加速器app

小麦加速器免费永久加速-快连加速器app

Investor Relations:
Argot Partners
Sam Martin / Maghan Meyers
(212) 600-1902
Email: sam@argotpartners.com / maghan@argotpartners.com

Media Relations:
Tracy Vineis
(617) 420-4839
Email: media@apellis.com

小麦加速器免费永久加速-快连加速器app

Sign up to receive email alerts whenever Apellis Pharmaceuticals, Inc. posts new information to the site. Just enter your email address and click Submit.

Sign Up
加速网络连接 Email Alerts RSS Feeds Contact IR
vp n下载大全  蚂蚁von  芒果快连加速器  上推特的旋风加速器  旋风最新官网  快连epn